PFM
UTHR icon

Premier Fund Managers’s United Therapeutics UTHR Stock Holding History

Premier Fund Managers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,800
Closed -$5.29M – 206
2024
Q4 		$5.29M Hold
14,800
– – 0.19% 86
2024
Q3 		$5.31M Buy
+14,800
New +$5M 0.19% 86
2023
Q2 		– Sell
-21,000
Closed -$4.6M – 229
2023
Q1 		$4.6M Sell
21,000
-3,000
-13% -$740K 0.18% 95
2022
Q4 		$6.62M Buy
+24,000
New +$6.06M 0.26% 85

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Premier Fund Managers's UTHR Position: Q1 2025 in Review

Premier Fund Managers sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 14,800 shares — an estimated $5.29M sold.

Premier Fund Managers first reported a position in UTHR in Q4 2022 and held it in 4 quarters. The position peaked at $6.62M in Q4 2022. 673 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Premier Fund Managers reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Premier Fund Managers sold 14,800 United Therapeutics shares in Q1 2025, an estimated $5.29M.
  • Premier Fund Managers first reported a position in United Therapeutics in Q4 2022 and held it in 4 quarters.
  • Premier Fund Managers's United Therapeutics position peaked at $6.62M in Q4 2022.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Premier Fund Managers's 13F filing for Q1 2025, filed 8 May 2025.